SGLT2 inhibitor after cardioversion to help keep sinus rhythm in AF with HFpEF
Official title: Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent Atrial Fibrillation Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Controlled Trial
Run by Samsung Medical Center · NCT07776054 · Data updated 2026-11-12
A large study will test whether starting an SGLT2 inhibitor after successful electrical cardioversion helps people with persistent atrial fibrillation and HFpEF stay in normal heart rhythm for at least a month.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 19 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Samsung Medical Center Academic / other |
| Locations | 1 site (Seoul, Seoul) |
| Status | Recruiting |
| Started | February 1, 2024 |
| Main results expected | August 1, 2027 |
| Study ends | September 1, 2027 |
| Registry record updated | August 20, 2026 |
| Trial ID | NCT07776054 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with persistent AF and HFpEF (H2FPEF ≥6 or HFA-PEFF ≥5) who have achieved sinus rhythm after electrical cardioversion.
✕Probably not a fit
Patients who have contraindications to SGLT2 inhibitors, no tolerance for the study drug, or whose AF recurs very early may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective, single-center study randomizes 200 adults with persistent AF and HFpEF to receive an SGLT2 inhibitor or standard care after successful electrical cardioversion. Participants are stratified by AF duration and left atrial size and all receive anticoagulation and possible antiarrhythmic therapy per guidelines for at least one month. The primary outcome is recurrence of atrial tachyarrhythmia within 1 month, assessed by ECG or continuous monitoring. The trial uses an intention-to-treat analysis with a per-protocol sensitivity analysis and aims for about 90% power to detect a meaningful difference between groups.
Why it matters
Potential benefit: If successful, the approach could reduce early recurrence of atrial arrhythmia and improve overall rhythm control after cardioversion.
How similar studies have gone: Previous studies suggest SGLT2 inhibitors benefit heart failure broadly, but their effect on maintaining sinus rhythm after cardioversion is not well established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥19 years * Persistent atrial fibrillation * H2FPEF score ≥6 or HFA-PEFF score ≥5 * Restoration of sinus rhythm after electrical cardioversion Exclusion Criteria: * Previous use of an SGLT2 inhibitor * Intracardiac thrombus on transesophageal echocardiography * Refusal to participate
Where it's running
-
Samsung Medical Center
Seoul, Seoul, South Korea Recruiting
Study contacts
- Study coordinator: Juwon Kim
- Email: abcd186a@naver.com
- Phone: +82-2-3410-2578
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals
This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.
-
Left-atrial Fibrosis in Persistent Atrial Fibrillation and Its Comorbidities
This study tests how comorbid conditions like sleep apnea and primary aldosteronism relate to left-atrial fibrosis and AF recurrence in patients undergoing ablation.
-
Dual Energy ablation with SmartTouch SF catheter in persistent atrial fibrillation
This study tests a pulsed field and radiofrequency ablation system to treat persistent atrial fibrillation in adults who have not responded well to prior medications.
-
Identifying AF patients who may need more than standard ablation using Volta AF-Xplorer II
This trial tests whether AI-identified dispersion areas during AF ablation can predict recurrence after a standard pulmonary vein isolation in patients with persistent AF.
-
4D intracardiac echocardiography to guide left atrial appendage occlusion procedures
A new 4D ICE catheter is being tested alongside standard imaging to see if it can safely guide left atrial appendage occlusion procedures for adults with atrial fibrillation.
-
Thoracoscopic vs Catheter Ablation as the First Rhythm Control in Atrial Fibrillation with a Large Left Atrium
This trial tests whether thoracoscopic surgical ablation is better at keeping atrial fibrillation under control than catheter ablation in people with persistent AF and a large left atrium who have not had an ablation before.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.